Cerus Corporation Reports 19% Revenue Growth to $60.2 Million in Q3 2025

Cerus Corporation reported its financial results for the third quarter of 2025, revealing a total revenue of $60.2 million, a 19% increase from $50.7 million in the same period last year. This growth was driven by a 15% rise in product revenue, which reached $52.7 million, primarily due to increased sales of disposable platelet kits in both the U.S. and Europe. Government contract revenue also saw a significant increase of 63%, totaling $7.5 million, largely attributed to enhanced funding from the Biomedical Advanced Research and Development Authority (BARDA) under a new agreement executed in late 2024.

In terms of profitability, Cerus reported a net loss of $20,000 for the quarter, a notable improvement compared to a net loss of $2.9 million in the same quarter of 2024. The company’s gross profit margin on product sales was 53%, down from 57% in the prior year, reflecting increased costs associated with tariffs and higher freight charges. For the nine months ending September 30, 2025, the net loss attributable to Cerus Corporation was $13.4 million, compared to a loss of $18.4 million for the same period in 2024.

Operationally, Cerus has made strides in expanding its product offerings and market presence. The company continues to focus on the commercialization of its INTERCEPT Blood System, which has received regulatory approvals in various countries, including the U.S. and several European nations. As of October 17, 2025, Cerus had 192,087,501 shares of common stock outstanding, reflecting ongoing efforts to manage its capital structure effectively. The company has also been actively working on its red blood cell system, which is currently in development and has not yet received marketing approval.

Looking ahead, Cerus anticipates continued growth in product revenue, driven by increased market acceptance of the INTERCEPT Blood System and ongoing commercialization efforts. The company expects government contract revenue to rise further as it ramps up activities under its agreements with BARDA and the U.S. Department of Defense. However, Cerus also faces challenges, including potential delays in regulatory approvals for its red blood cell system and the need to navigate a complex global supply chain impacted by geopolitical tensions and inflationary pressures. The company remains committed to addressing these challenges while pursuing its strategic objectives in the blood safety market.